文献速递预防保健、筛查与疫苗妇女保健

英格兰HPV疫苗接种计划对宫颈癌及CIN3发病率的影响:社会经济剥夺程度分析

Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
PubMed 文献 · BMJ · 2024-05-15

该基于人群的观察性研究利用2006年1月至2020年6月英格兰20-64岁女性数据(宫颈癌29 968例,CIN3 335 228例),在额外12个月随访中发现,常规接种队列(12-13岁)宫颈癌和CIN3年龄标化发病率分别较未接种参考队列降低83.9%和94.3%,且在所有五个剥夺水平中均有效。

要点

  • 常规接种HPV疫苗的12-13岁女性队列,宫颈癌和CIN3发病率分别降低83.9%和94.3%。
  • 截至2020年中,HPV疫苗估计预防了687例宫颈癌和23 192例CIN3。
  • 补接种队列中,CIN3下降幅度在剥夺程度最低地区大于最高地区。

核心结论

  • 英格兰HPV疫苗接种计划的高有效性在额外12个月随访中持续,且在所有五个社会经济剥夺水平中均与宫颈癌和CIN3发病率大幅降低相关。

研究设计与样本

  • 观察性研究,纳入2006年1月至2020年6月居住在英格兰的20-64岁女性,包括29 968例宫颈癌和335 228例CIN3诊断。
  • 英格兰于2008年国家引入HPV疫苗接种,常规提供给12-13岁女孩,2008-10年补接种活动针对<19岁较大青少年。

主要发现

  • 在常规12-13岁接种队列中,额外12个月随访(2019年7月1日至2020年6月30日)的宫颈癌和CIN3调整年龄标化发病率分别较从未接种参考队列低83.9%(95%CI 63.8%至92.8%)和94.3%(95%CI 92.6%至95.7%)。
  • 截至2020年中,HPV疫苗接种估计预防了687例(95%CI 556至819)宫颈癌和23 192例(95%CI 22 163至24 220)CIN3。
  • 最高发病率仍见于最贫困地区女性,但HPV疫苗接种计划在所有五个剥夺水平均有大幅效果。
  • 在补接种女性中,CIN3发病率下降在剥夺程度最低地区大于最高地区:16-18岁接种者下降40.6%对29.6%,14-16岁接种者下降72.8%对67.7%。
  • 参考未接种组中宫颈癌发病率从高剥夺到低剥夺的强烈下降梯度在接种组中不再存在。

临床怎么用

  • 应继续推进HPV疫苗常规接种和补接种,尤其关注贫困地区女性以提高公平性。
  • HPV疫苗接种可显著降低所有社会经济层次女性的宫颈癌和CIN3负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To replicate previous analyses on the effectiveness of the English human papillomavirus (HPV) vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) using 12 additional months of follow-up, and to investigate effectiveness across levels of socioeconomic deprivation. DESIGN: Observational study. SETTING: England, UK. PARTICIPANTS: Women aged 20-64 years resident in England between January 2006 and June 2020 including 29 968 with a diagnosis of cervical cancer and 335 228 with a diagnosis of CIN3. In England, HPV vaccination was introduced nationally in 2008 and was offered routinely to girls aged 12-13 years, with catch-up campaigns during 2008-10 targeting older teenagers aged <19 years. MAIN OUTCOME MEASURES: Incidence of invasive cervical cancer and CIN3. RESULTS: In England, 29 968 women aged 20-64 years received a diagnosis of cervical cancer and 335 228 a diagnosis of CIN3 between 1 January 2006 and 30 June 2020. In the birth cohort of women offered vaccination routinely at age 12-13 years, adjusted age standardised incidence rates of cervical cancer and CIN3 in the additional 12 months of follow-up (1 July 2019 to 30 June 2020) were, respectively, 83.9% (95% confidence interval (CI) 63.8% to 92.8%) and 94.3% (92.6% to 95.7%) lower than in the reference cohort of women who were never offered HPV vaccination. By mid-2020, HPV vaccination had prevented an estimated 687 (95% CI 556 to 819) cervical cancers and 23 192 (22 163 to 24 220) CIN3s. The highest rates remained among women living in the most deprived areas, but the HPV vaccination programme had a large effect in all five levels of deprivation. In women offered catch-up vaccination, CIN3 rates decreased more in those from the least deprived areas than from the most deprived areas (reductions of 40.6% v 29.6% and 72.8% v 67.7% for women offered vaccination at age 16-18 and 14-16, respectively). The strong downward gradient in cervical cancer incidence from high to low deprivation in the reference unvaccinated group was no longer present among those offered the vaccine. CONCLUSIONS: The high effectiveness of the national HPV vaccination programme previously seen in England continued during the additional 12 months of follow-up. HPV vaccination was associated with a substantially reduced incidence of cervical cancer and CIN3 across all five deprivation groups, especially in women offered routine vaccination.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Falcaro M, Soldan K, Ndlela B, et al. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study. BMJ. 2024. PMID: 38749552. doi:10.1136/bmj-2023-077341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。